Mural Oncology Investigational Site

Washington D.C., District of Columbia 20007

0 studies enrolling now · 1 studies all time

What they study most

Advanced Solid Tumors

Studies at this site

• A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) — Completed